Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that Ms. Anu Sharma has joined the Company as Senior Sales and Marketing Manager. John DiBella, vice president of marketing and sales for Simulations Plus, said, “Although our scientific staff has always been an integral part of our marketing and sales activities, we wanted to further strengthen the marketing and sales department with a full-time field person for our exciting and growing ADMET Design Suite™, namely, ADMET Predictor™, MedChem Studio™, and MedChem Designer™. Anu brings a strong background in both pharmaceutical chemistry and software sales with a master’s degree in chemistry as well as an MBA. Her considerable industry experience as a bench chemist and later in software sales and support make her an ideal candidate for increasing sales in the cheminformatics software and services side of the business.” About Simulations Plus, Inc. Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com. Follow us on TwitterSafe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.